HomeClinics HomeAbout ClinicsAll ClinicsHot TopicsAdvancesSpecial OffersCME
Logo
Search for

Volume 93, Issue 6, Pages 1291-1303 (November 2009)


View previous. 13 of 16 View next.

Evaluation and Management of Psoriasis: An Internist's Guide

Danielle Levine, BAab, Alice Gottlieb, MD, PhDaCorresponding Author Informationemail address

Psoriasis is a debilitating chronic skin condition that afflicts millions of patients worldwide. Patients experiencing psoriasis report a magnitude of impaired quality of life that is often similar to that of patients who have heart failure and cancer. Many patients who have psoriasis are even themselves at risk for developing heart disease, metabolic syndrome, certain cancers, and psychiatric illness. Therefore, primary care physicians must appreciate the current psoriatic disease model and share a basic understanding of psoriasis management. This article reviews the epidemiology, clinical features, pathogenesis, comorbidities, and treatment of psoriasis, with special emphasis placed on the new class of medications, biologics, which are revolutionizing the management of the disease.

a Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, 800 Washington Street, Box #114, Boston, MA 02111, USA

b Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, 20 Stedman Street, Box #1, Boston, MA 02446, USA

Corresponding Author InformationCorresponding author.

 Disclosures: Neither manuscript nor any other related manuscripts have been published or submitted.

 Alice Gottlieb, MD, PhD (as of November 1, 2008): Almost all income paid to employer directly. Speakers' Bureau Memberships: Amgen Inc; Wyeth Pharmaceuticals. Current Consulting/Advisory Board Agreements: Amgen Inc; Centocor, Inc; Wyeth Pharmaceuticals; Celgene Corp; Bristol Myers Squibb Co; Beiersdorf, Inc; Warner Chilcott; Abbott Laboratories; Roche; Sankyo; Medarex; Kemia; Celera; TEVA; Actelion; UCB; Novo Nordisk; Almirall; Immune Control; RxClinical; Dermipsor Ltd; Medacorp; DermiPsor; Can-Fite; Incyte; Pure-Tech; Magen Biosciences. Research/Educational Grants: Centocor; Amgen; Wyeth; Immune Control; Celgene; Pharmacare; Incyte; Abbott Laboratories; Pfizer (pending); Novo Nordisk (pending).

PII: S0025-7125(09)00108-4

doi:10.1016/j.mcna.2009.08.003


View previous. 13 of 16 View next.